Treatment of Acne Vulgaris Using NAFL in Combination With Isotretinoin and Pricking Blood Therapy

• Status: Completed
• Trial end date: 2018-10-05
• Target enrollment: 0
• Participant gender: All

Summary

BACKGROUND Isotretinoin remains one of the first line medications for moderate-to-severe acne vulgaris (AV) but its side effect is a major concern for Asian patients.

OBJECTIVE Investigators aimed to evaluate the efficacy and safety of the 1,565 nm non-ablative fractional laser (NAFL) in combination with isotretinoin and pricking blood therapy (PBT) for treatment of AV.

METHODS A retrospective analysis of 60 patients with moderate-to-severe AV was performed. Four groups (n=15) were evaluated: 1,565nm NAFL alone, oral isotretinoin alone, double therapy (NAFL + isotretinoin) and triple therapy (NAFL + isotretinoin + PBT).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: xjpfW
• Treatments: Isotretinoin

Criteria

Inclusion Criteria:

• Patients ranged in age from twenty to forty years old

• Clinically diagnosed as a facial acne patient

• The patients meet the needs of the research program of this topic

Exclusion Criteria:

• pregnancy

• liver or kidney functional abnormality

• skin ulceration with active bacteria

• fungal or viral infection or skin cancer

• coagulation disorders

• patients on drugs of agents

• systemic diseases such as cardiovascular disease

• epilepsy

• diabetes

• immunodeficiency disease

• active psoriasis